NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Pirouette Pharma

Pirouette Pharma

Private
Portsmouth, New HampshireHealthcare & Life Scienceshttps://www.pirouettepharma.com/

Last Round

Seed Round

Mar 18, 2026

Est. Valuation

$55M

Total Funding Raised

$23.76M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Pirouette Pharma is a pharmaceutical company that develops a platform of automated, disk-shaped auto-injectors designed for affordability, portability, and ease of use.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Biotechnology, Patient Engagement

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share, Hardware Sales

AI Layer

Non-AI

Keywords

auto-injectordrug delivery devicecombination productpatient complianceepinephrine auto-injectornaloxone auto-injectormedication adherenceneedle anxietymedical device platform505(b)(2) pathway351(k) pathwaydrug-device combinationself-administrationmedtechpharma tech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Pirouette Pharma Comps

Public and private peers based on sector, stage, and business model.

Pirouette Pharma comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Pirouette Pharma Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Seed RoundMar 18, 2026
CrowdfundingMar 14, 2025
CrowdfundingMay 7, 2024
Series A ExtensionMay 31, 2022
GrantSep 20, 2021
Series A
Aug 1, 2021

Key People

Founding team and executive leadership

Conor Cullinane

President CEO, Co-Founder

Founding Team

Eli Kapas

CTO, CTO

Executive Team

Matthew Kane

Chief Operating Officer

Executive Team

Pirouette Pharma Investors

Notable investors and investment history

Pirouette Pharma investors
InvestorRounds
National Institute on Drug Abuse (NIDA)Grant
NIH RADxGrant
GaingelsCrowdfunding, Series A
Magic FundCrowdfunding
Safar PartnersCrowdfunding, Series A, Seed
Asymmetry VenturesCrowdfunding
Y CombinatorCrowdfunding, Series A, Accelerator

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 18, 2026

    $1.08M raised in Seed Round.

  • Sep 20, 2021

    $327K grant from National Institute on Drug Abuse and NIH RADx.

Pirouette Pharma Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Pirouette Pharma Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Pirouette Pharma's valuation, stock price, and market status.

Firmographic Details

HeadquartersPortsmouth, New Hampshire
Employee Range29
Year Founded2017
Last FundingMar 18, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.